48,xyyy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: 48X005 MIFTS: 41	48,xyyy Categories: Fetal diseases, Mental diseases, Neuronal diseases, Oral diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for 48,xyyy

MalaCards integrated aliases for 48,xyyy:

Name: 48,xyyy ¹⁹ ⁷⁵

48,xyyy Syndrome ⁵⁸

Xyyy Syndrome ⁷⁵

Characteristics:

Prevelance:

48,xyyy Syndrome: <1/1000000 (Worldwide) ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Neuronal diseases Reproductive diseases Oral diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Congenital malformations, deformations and chromosomal abnormalities

Chromosomal abnormalities, not elsewhere classified

Other sex chromosome abnormalities, male phenotype, not elsewhere classified

Other specified sex chromosome abnormalities, male phenotype

Orphanet: ⁵⁸

Rare neurological diseases

Rare infertility disorders

Developmental anomalies during embryogenesis

Sources

Summaries for 48,xyyy

GARD: ¹⁹ A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.

MalaCards based summary: 48,xyyy, also known as 48,xyyy syndrome, is related to 49,xyyyy syndrome and down syndrome. The drugs Chlorhexidine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and lung, and related phenotypes are high palate and short neck

Orphanet: ⁵⁸ A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.

Wikipedia: ⁷⁵ XYYY syndrome, also known as 48,XYYY, is a chromosomal disorder in which a male has two extra copies of... more...

Sources

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)

#	Related Disease	Score
1	49,xyyyy syndrome	11.2
2	down syndrome	10.4
3	47 xxx syndrome	10.4
4	radioulnar synostosis, nonsyndromic	10.2
5	hypogonadotropic hypogonadism	10.2
6	turner syndrome	10.2
7	aortic valve disease 1	10.1
8	coarctation of aorta	10.1
9	contractural arachnodactyly, congenital	10.1
10	cryptorchidism, unilateral or bilateral	10.1
11	aortic valve disease 2	10.1
12	aortic valve disease 3	10.1
13	hypospadias	10.1
14	synostosis	10.1
15	radioulnar synostosis	10.1
16	49, xxxxy syndrome	10.1

Graphical network of the top 20 diseases related to 48,xyyy:

Sources

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

⁵⁸ ³⁰ (show all 32)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	high palate ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000218
2	short neck ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000470
3	global developmental delay ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001263
4	depressed nasal bridge ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0005280
5	hypertelorism ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000316
6	delayed speech and language development ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000750
7	pes planus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001763
8	intellectual disability, mild ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001256
9	thick lower lip vermilion ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000179
10	recurrent upper respiratory tract infections ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002788
11	acne ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001061
12	abnormal dermatoglyphics ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0007477
13	epicanthus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000286
14	asthma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002099
15	azoospermia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000027
16	long philtrum ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000343
17	radioulnar synostosis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002974
18	tall stature ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000098
19	feeding difficulties ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0011968
20	dislocated radial head ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003083
21	aggressive behavior ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000718
22	abnormal renal morphology ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012210
23	low frustration tolerance ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000744
24	male hypogonadism ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000026
25	impulsivity ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100710
26	primary gonadal insufficiency ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008193
27	irregularly spaced teeth ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0006316
28	enamel hypoplasia ³⁰	Hallmark (90%)		HP:0006297
29	intellectual disability ⁵⁸		Very frequent (99-80%)
30	behavioral abnormality ⁵⁸		Very frequent (99-80%)
31	abnormality of the foot ⁵⁸		Very frequent (99-80%)
32	hypoplasia of dental enamel ⁵⁸		Very frequent (99-80%)

Sources

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 384)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 4

55-56-1

2713 9552079

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Cobicistat

Approved

Phase 4

1004316-88-4

24950485 25151504

Rilpivirine

Approved

Phase 4

500287-72-9

6451164

Elvitegravir

Approved

Phase 4

697761-98-1

23083982 5277135

Amantadine

Approved

Phase 4

768-94-5

2130

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Rifabutin

Approved, Investigational

Phase 4

72559-06-9

46783538 6323490

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Lamivudine

Approved, Investigational

Phase 4

134678-17-4

60825

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

Abacavir

Approved, Investigational

Phase 4

136470-78-5, 188062-50-2

441300

Zidovudine

Approved

Phase 4

30516-87-1

35370

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Peginterferon alfa-2b

Approved

Phase 4

215647-85-1, 99210-65-8

Nevirapine

Approved

Phase 4

129618-40-2

4463

Darunavir

Approved

Phase 4

635728-49-3, 206361-99-1

213039

Cefuroxime

Approved

Phase 4

55268-75-2

5479529

Cefazolin

Approved

Phase 4

25953-19-9

33255

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Insulin lispro

Approved

Phase 4

133107-64-9

16132438

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Acetaminophen

Approved

Phase 4

103-90-2

1983

Etravirine

Approved

Phase 4

269055-15-4

193962

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Glimepiride

Approved

Phase 4

93479-97-1

3476

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Bismuth subsalicylate

Approved, Vet_approved

Phase 4

14882-18-9

53629521 16682734

Amprenavir

Approved, Investigational

Phase 4

161814-49-9

65016

Nelfinavir

Approved

Phase 4

159989-64-7

64143

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Indinavir

Approved

Phase 4

150378-17-9

5362440

Didanosine

Approved

Phase 4

69655-05-6

50599

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Omalizumab

Approved, Investigational

Phase 4

242138-07-4

Interferon alfacon-1

Approved, Investigational

Phase 4

118390-30-0

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4, 155141-29-0

77999

Hydroxyurea

Approved

Phase 4

127-07-1

3657

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Hydromorphone

Approved, Illicit

Phase 4

466-99-9, 71-68-1

5284570

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Orphenadrine

Approved

Phase 4

83-98-7

4601

Tobramycin

Approved, Investigational

Phase 4

32986-56-4

36294

Framycetin

Approved, Experimental, Vet_approved

Phase 4

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Fluocinolone acetonide

Approved, Investigational, Vet_approved

Phase 4

67-73-2

6215

Pamidronic acid

Approved

Phase 4

40391-99-9

4674

Golimumab

Approved

Phase 4

476181-74-5

Interventional clinical trials:

(show top 50) (show all 336)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects	Unknown status	NCT00011895	Phase 4	Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
2	Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.	Unknown status	NCT01883596	Phase 4	0.12% chlorhexidine solution;Placebo
3	An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8	Unknown status	NCT01683786	Phase 4	Pegintron + Riba
4	Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy	Unknown status	NCT02981212	Phase 4	Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
5	Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.	Unknown status	NCT00751153	Phase 4	Raltegravir and Atazanavir
6	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	Unknown status	NCT00426296	Phase 4	atazanavir (Reyataz);ritonavir (Norvir)
7	Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks	Unknown status	NCT02470650	Phase 4	elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
8	Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection	Unknown status	NCT00127777	Phase 4	Amantadine sulphate (in addition to standard treatment)
9	Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.	Unknown status	NCT00611819	Phase 4	Peg interferon + Ribavirin
10	A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks	Unknown status	NCT02474316	Phase 4	Peginterferon alfa-2a;nucleos(t)ide analgoue
11	Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy	Unknown status	NCT01059422	Phase 4	Raltegravir; Abacavir/Lamivudine
12	A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)	Unknown status	NCT02404233	Phase 4	darunavir/cobicistat;rilpivirine
13	A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement	Unknown status	NCT00354445	Phase 4	pegaptanib sodium (Macugen)
14	Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)	Completed	NCT02720107	Phase 4	fingolimod
15	A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL.	Completed	NCT01928407	Phase 4	DARUNAVIR;ATAZANAVIR
16	24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial	Completed	NCT04303390	Phase 4	Cefuroxime;Cefazolin
17	A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps	Completed	NCT00461331	Phase 4	Insulin Aspart;Insulin Lispro
18	Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus	Completed	NCT02761629	Phase 4	Peg-Interferon Alpha-2A;Ribavirin
19	An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy	Completed	NCT02068365	Phase 4	Pegyinterferon-alfa-2a
20	A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen.	Completed	NCT00389402	Phase 4	saquinavir/ritonavir;atazanavir/ritonavir
21	A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function	Completed	NCT00641082	Phase 4	Clevudine;Adefovir dipivoxil
22	Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial	Completed	NCT02280486	Phase 4	Saxagliptin;Glimepiride
23	Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan	Completed	NCT00495131	Phase 4	Pegylated interferon alfa-2a plus ribavirin
24	A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.	Completed	NCT00389194	Phase 4	continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
25	Multicenter, Prospective, Comparative, Randomized Controlled Clinical Trial to Evaluate the Performance and the Safety of Promelaxin® Micro-enemas Vs. Macrogol 4000 Per os in the Treatment of Functional Chronic Constipation in Children Aged Between 6 and 48 Months.	Completed	NCT02751411	Phase 4	Macrogol 4000
26	A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B	Completed	NCT00441974	Phase 4	adefovir dipivoxil
27	Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time	Completed	NCT00192660	Phase 4	Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20)
28	XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria	Completed	NCT02392624	Phase 4	Omalizumab;Placebo
29	Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9: a Phase IV, Randomized, Open-labeled, Multicenter Trial Comparing 24-week vs. 48-week Therapy	Completed	NCT00575224	Phase 4	Pegylated interferon and ribavirin
30	A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks	Completed	NCT00082394	Phase 4	Trizivir;atazanavir;Combivir
31	A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s)	Completed	NCT00005018	Phase 4	Hydroxyurea;Abacavir sulfate;Efavirenz;Didanosine
32	A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)	Completed	NCT00038506	Phase 4	abacavir/lamivudine/zidovudine;tenofovir
33	A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age	Completed	NCT03143101	Phase 4
34	A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects	Completed	NCT01045369	Phase 4	Kaletra and Intelence Tablets
35	AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.	Completed	NCT00241605	Phase 4	rosiglitazone/metformin
36	Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours?	Completed	NCT00216736	Phase 4	Dexamethasone;placebo
37	A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy	Completed	NCT00266318	Phase 4	Interferon Alfacon-1 and Ribavirin
38	Timing of IUI 24 or 48 Hours After Spontaneous LH Peak: a Randomised Controlled Trial	Completed	NCT01622023	Phase 4
39	Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C	Completed	NCT00993122	Phase 4	ribavirin pre-treatment
40	48 Week Pilot Trial Assessing the Efficacy of Pioglitazone, Atorvastatin, Pegasys and Weight Based Ribavirin in Chronic Hepatitis C, Genotype 1 Patients Who Have Previously Relapsed or Did Not Respond to PegInterferon /Ribavirin Therapy	Completed	NCT00926614	Phase 4	pioglitazone (Actos);atorvastatin (Lipitor)
41	Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee Arthroplasty (TKA). Prospective, Randomized, Open-label Trial to Determine if Switching From Oral to Intravenous Acetaminophen and Orphenadrine for 48 Hours After TKA Improves Outcomes.	Completed	NCT02449369	Phase 4	Preop acetaminophen IV;Preop orphenadrine IV;Postop oral oxycodone & acetaminophen;Postop hydromorphone IV;Postop oral orphenadrine;Postop oral oxycodone;Postop acetaminophen IV;Postop orphenadrine IV
42	A Randomized, Open Labeled, Active-Controlled Trial of 24-Week Versus 48-Week Courses of Peg-Interferon Alpha Plus Ribavirin for Genotype-1 Infected Chronic Hepatitis C Patients	Completed	NCT00629967	Phase 4	pegylated interferon alpha 2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
43	Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study.	Completed	NCT02166853	Phase 4	sevoflurane;midazolam
44	A Modified 48 Hour Patch Test of Neo-Synalar Cream, Sodium Lauryl Sulfate (Positive Control) and Saline (Negative Control)	Completed	NCT02168478	Phase 4	Neo-Synalar Cream
45	Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial	Completed	NCT01718951	Phase 4	golimumab;Pamidronate
46	A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.	Completed	NCT01573572	Phase 4	pegaptanib sodium injection
47	Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up	Completed	NCT01471821	Phase 4	antiretroviral treatment
48	A Randomized Controlled Study Compares the 48 Weeks Results of HIV-1 RNA Between Ritonavir-boosted Lopinavir Monotherapy and Ritonavir-boosted Lopinavir + Optimized Background Regimens in HIV-1 Infected Patients Who Have HIV-1 RNA <50 Copies/ml More Than 6 Months While Receiving Salvage PI-based Regimen and Previously Failed NNRTI-based Regimen	Completed	NCT01189695	Phase 4	Ritonavir-boosted lopinavir;optimized background regimens (OBRs)
49	A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.	Completed	NCT01775137	Phase 4	TBM100
50	A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys®) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)	Completed	NCT01277601	Phase 4	TDF;Peg-IFN

Search NIH Clinical Center for 48,xyyy

Sources

Genetic Tests for 48,xyyy

Sources

Anatomical Context for 48,xyyy

Organs/tissues related to 48,xyyy:

MalaCards : Liver, Spinal Cord, Lung, Heart, Prostate, Bone Marrow, Bone

Sources

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)

#	Title	Authors	PMID	Year
1	Hypoventilation in the PACU is associated with hypoventilation in the surgical ward: Post-hoc analysis of a randomized clinical trial. ⁶²	Rivas E...Turan A	36370589	2023
2	Effects of a single dose of long-acting FSH on testicular blood flow, testicular echotexture, and circulating testosterone, estradiol, and nitric oxide in rams during the non-breeding season. ⁶²	Samir H...El-Sherbiny HR	36219897	2023
3	Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy. ⁶²	Kling JM...Miller VM	36395695	2023
4	Oil fly ash as a promise larvicide against the Aedes aegypti mosquitoes. ⁶²	Bosly HAE...Saeed A	36341780	2023
5	Highly efficient in-situ cleaner degradation of difenoconazole by two novel dominant strains: Microflora diversity, monoclonal isolation, growth factor optimization, intermediates, and pathways. ⁶²	Chen X...Liu A	36244419	2023
6	Influence of microplastics on the toxicity of chlorpyrifos and mercury on the marine microalgae Rhodomonas lens. ⁶²	Pinto EP...Bellas J	36273570	2023
7	Corrigendum to ArtifactID: Identifying artifacts in low-field MRI of the brain using deep learning Magnetic Resonance Imaging Volume 89, June 2022, Pages 42-48. ⁶²	Manso Jimeno M...Geethanath S	35396147	2023
8	Corrigendum to "A study of MRI gradient echo signals from discrete magnetic particles with considerations of several parameters in simulations" [Magn. Reson. Imaging, 48, May 2018, 129-137]. ⁶²	Kokeny P...Xie H	30826151	2023
9	Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest. ⁶²	Nana T...Chibabhai V	35811020	2022
10	Reducing 48-h emergency department revisits and subsequent admissions: a retrospective study of increased emergency medicine resident floor coverage. ⁶²	Palungwachira P...Savatmongkorngul S	36474146	2022
11	Gastrointestinal colonization by OXA-48-producing Enterobacterales: risk factors for persistent carriage. ⁶²	Lima O...Perez-Rodriguez MT	36205803	2022
12	Corrigendum to "Molecular basis of bacterial disinfectant resistance" [Drug Resist. Updates 48 (2020) 100672]. ⁶²	Mc Carlie S...Bragg RR	36252361	2022
13	Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. ⁶²	Lombardi F...Di Giambenedetto S	35758043	2022
14	Correction to Lancet HIV 2022; 9: e438-48. ⁶²		35659003	2022
15	Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis. ⁶²	Frey MK...Sharaf RN	35960887	2022
16	Ambulatory central BP and arterial stiffness in patients with and without intradialytic hypertension. ⁶²	Theodorakopoulou MP...Sarafidis PA	35986597	2022
17	Bilateral lysis of aortic saddle thrombus with early tissue plasminogen activator (BLASTT): a prospective, randomized, placebo-controlled study in feline acute aortic thromboembolism. ⁶²	Guillaumin J...Bonagura JD	36350753	2022
18	Impact of the Timing of Endoscopic Retrograde Cholangiopancreatography for the Treatment of Acute Cholangitis: A Meta-analysis and Systematic Review. ⁶²	Lyu Y...Cheng Y	36223305	2022
19	Personalized health risk assessment based on single-cell RNA sequencing analysis of a male with 45, X/48, XYYY karyotype. ⁶²	Koczkowska M...Piotrowski A	36460769	2022
20	Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication. ⁶²	Mori H...Kanai T	35000515	2022
21	Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature. ⁶²	Valiente De Santis LB...Reguera Iglesias JM	36183238	2022
22	Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. ⁶²	Kamran A...Patel N	33980104	2022
23	Infant nutrition (donor human milk vs. maternal milk) and long-term neurodevelopmental and growth outcomes in very low birth weight infants. ⁶²	Bajwa RU...Vora N	35703947	2022
24	Cytotoxicity and anti-biofilm properties of novel hybrid-glass-based caries infiltrant. ⁶²	Nedeljkovic I...Kleverlaan CJ	36437129	2022
25	Speech and language development and genotype-phenotype correlation in 49 individuals with KAT6A syndrome. ⁶²	St John M...Morgan AT	35892268	2022
26	Comparison of Pregnancy Outcomes of Previable and Periviable Rupture of Membranes After Laser Photocoagulation for Twin-Twin Transfusion Syndrome. ⁶²	Forde B...Habli M	36357989	2022
27	Comparison of Femoral Nerve Catheter, Adductor Canal Catheter, and Periarticular Liposomal Bupivacaine Infiltration for Postoperative Analgesia after Primary Total Knee Arthroplasty. ⁶²	Dobson SW...Henshaw DS	36470364	2022
28	Comparison of Ketamine, Dexmedetomidine and Lidocaine in Multimodal Analgesia Management Following Sleeve Gastrectomy Surgery: A Randomized Double-Blind Trial. ⁶²	Ustun YB...Kaya C	35382963	2022
29	Efficacy of Electroacupuncture Combined with Intravenous Patient-controlled Analgesia after Cesarean Section: A Randomized Clinical Trial. ⁶²	Jin Y...Wang L	36464237	2022
30	Efficacy of postoperative analgesia with duloxetine in posthemorrhoidectomy pain: a prospective, randomized, double-blind and placebo-controlled trial. ⁶²	Gerber MT...de Oliveira Filho GR	36457090	2022
31	Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. ⁶²	Nasrallah S...Gomez LM	33771091	2022
32	Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study. ⁶²	Chen HY...Su WL	36464717	2022
33	Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. ⁶²	Degasperi E...Lampertico P	35973578	2022
34	The minimal invasive surfactant therapy: experience from a low resource setting. ⁶²	Ajanwaenyi J...Okolo A	33491516	2022
35	The complex lipid, SPPCT-800, reduces lung damage, improves pulmonary function and decreases pro-inflammatory cytokines in the murine LPS-induced acute respiratory distress syndrome (ARDS) model. ⁶²	Sordillo PP...Labbe SM	35786152	2022
36	A New Risk Score to Predict Intensive Care Unit Admission for Patients with Acute Pancreatitis 48 Hours After Admission: Multicenter Study. ⁶²	Yuan L...Xu J	36462125	2022
37	WD repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing c-Myc. ⁶²	Li B...Zuo S	36403194	2022
38	Detection and Characterization of Paraproteinemia in Canine Chronic B-cell Lymphocytic Leukemia Using Routine and Free Light Chain Immunofixation. ⁶²	Harris RA...Moore AR	35883213	2022
39	Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. ⁶²	Matsumori Y...Sakai F	36136232	2022
40	Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study. ⁶²	Nguyen HT...Vu TTP	36472791	2022
41	Analgesia Effect of Ultrasound-Guided Transversus Abdominis Plane Block Combined with Intravenous Analgesia After Cesarean Section: A Double-Blind Controlled Trial. ⁶²	Xue M...Shen X	35980557	2022
42	Klebsiella Species and Enterobacter cloacae Isolates Harboring blaOXA-181 and blaOXA-48: Resistome, Fitness Cost, and Plasmid Stability. ⁶²	Mahazu S...Saito R	36453894	2022
43	Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. ⁶²	Kedia S...Ahuja V	35973787	2022
44	Durable biochemical response and safety with oral octreotide capsules in acromegaly. ⁶²	Samson SL...Melmed S	36173649	2022
45	Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. ⁶²	Schilsky ML...CHELATE trial investigators	36183738	2022
46	Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging. ⁶²	Lundin B...Ljung R	36469433	2022
47	Shoulder-Touch test to reveal incongruencies in persons with functional motor disorders. ⁶²	Geroin C...Tinazzi M	36038356	2022
48	Modulating the lipid profile of blastocyst cell membrane with DPPC multilamellar vesicles. ⁶²	De Rossi H...Gouveia Nogueira MF	35713365	2022
49	A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History. ⁶²	Berl V...Evans M	35787693	2022
50	Association between early, small creatinine elevation and severe acute kidney injury in critically ill adult patients. ⁶²	Kuo G...Chang CH	36084379	2022